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Abstract
Breast cancer patients rarely present with isolated axillary lymph node metastasis without any clinical or radiological evidence of 
primary tumor. Identification of the primary site of tumor helps in planning appropriate patient management which has definite 
impact on patient’s survival. We present here a case of 30-year-old female who presented with isolated right axillary lymph 
node metastasis with no evidence of primary tumor clinically. Conventional imaging modalities were negative for primary site. 
She underwent whole body 18F-Flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) 
and it contributed significantly in early detection of occult primary tumor in right breast.
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Background
Breast cancer presenting as an isolated axillary lymph node 
metastasis with no clinical and radiological evidence of primary 
tumor is uncommon. The incidence is low ranging from 0.3–0.8% 
of all breast cancer patients [1]. American Joint Committee on 
Cancer has classified it as T0, N1-2, M0, Stage II–III [1]. Identi-
fication of primary site in such cases remains a challenge and 
has definite impact on patient’s survival [1]. Clinical examination, 
noninvasive and invasive modalities like mammography, breast 
magnetic resonance imaging (MRI), ultrasound (USG), fine nee-
dle aspiration cytology (FNAC) and excision biopsy are used for 
diagnosis of primary site. The treatment of isolated axillary lymph 
node metastasis is controversial. Traditionally the choice of treat-
ment for isolated axillary lymph node metastasis is mastectomy 
and axillary lymph node dissection [1, 2]. But in one third of pa-
tients histopathologic examination of the mastectomy specimen 
may not reveal the primary tumor [3, 4]. Hence there is clearly 
a need for noninvasive imaging modality for primary site detection 
to avoid unnecessary morbidity and for appropriate management. 
Here we report a case of 30-year-old female patient with isolated 
right axillary lymph node metastasis and unknown primary site in 
whom 18F-Flurodeoxyglucose (FDG) positron emission tomography 
(PET)/computed tomography (CT) had an important role in early 
identification of primary site in right breast.
Case report
A 30-year-old female presented with right axillary lymphade- 
nopathy. FNAC revealed metastatic carcinoma and excisional 
biopsy showed metastatic adenocarcinoma. She was extensively 
investigated for primary site. Conventional imaging modalities like 
mammography, non contrast enhanced CT chest and abdomen, 
USG neck and abdomen, upper gastrointestinal endoscopy 
showed no evidence of any primary site. 18F-FDG PET/CT was ad-
vised and primary site could not be localized (Figure 1). Patient 
underwent chemotherapy and kept on follow up. Mammography, 
non-contrast enhanced CT of neck, chest and abdomen were 
done during the follow up and revealed no evidence of primary 
tumor. After nine months of the initial PET/CT study, she came for 
follow up 18F-FDG PET/CT for search of primary site which revealed 
FDG avid small subcentimeter nodular lesion in the upper outer 
quadrant of right breast which was suggested as the primary site 
and active metastatic disease in subcentimeter right subpectoral 
lymph nodes (Figure 2). She underwent mastectomy and adjuvant 
chemotherapy. Histopathology from right mastectomy specimen 
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showed infiltrating ductal carcinoma (Figure 3) and now she is clini-
cally disease free post treatment.
Discussion
Breast cancer presenting as isolated axillary lymph node me-
tastasis is an uncommon form of stage II disease and management 
becomes difficult without identification of primary site. Halsted first 
described two patients of occult primary breast cancer with axillary 
nodes involvement [2]. After axillary lymph node metastasis the 
time of appearance of primary breast tumor varies from 0.5 to 
5 years [5]. Diagnostic and treatment protocols are not very well 
established. The prognosis for occult breast cancer with isolated 
axillary lymph nodes appears to be better than stage II palpable 
breast carcinoma. Hence the proper identification of primary site 
and appropriate management leads to good prognosis. Lymphoma 
is the most common malignant cause of axillary lymphadenopathy 
followed by breast carcinoma. More than 90% of patients with 
axillary lymph node metastasis have primary tumor in breast. Pri-
mary tumor from other sites like thyroid, lung, stomach, pancreas, 
ovary and colon can also metastasize to axillary lymph nodes, but 
they are less common [6]. In cases of occult breast cancer mam-
mography, breast USG, CT and MRI are routinely used for primary 
tumor identification. The sensitivity of mammography is limited 
and varies from 0 to 56% percent for detection of occult primary 
site in breast. It may be due to dense breast parenchyma causing 
non visualization of small primary tumors. Contrast-enhanced CT 
and MRI has important role in primary site detection. But smaller 
non-enhancing lesions lesser than its resolution may be missed [7]. 
Morris et al. showed that contrast-enhanced MRI has an identifica-
tion rate of 75% [8]. Orel et al. reported 86% sensitivity of breast 
MR imaging in identification of occult breast primary in patients with 
axillary lymph node metastasis [9].
The role of 18F-FDG PET/CT has also been evaluated. Takaba-
take et al. described that 18F-FDG PET/CT was a helpful option for 
the diagnosis of primary sites in two cases of occult breast cancer 
where conventional imaging studies had difficulty in identifying 
[10]. Owaki et al. reported a case of 0.9 cm diameter primary 
breast carcinoma detected by FDG PET-CT [11]. It is a well-known 
fact that 18F-FDG PET/CT as a functional tumor imaging modality, 
identifies the early pathological changes before obvious anatomi-
cal changes happen. Even though it is not routinely recommended 
for initial tumor and locoregional staging of breast cancer because 
of its reduced sensitivity, it is reported to be specific once the 
primary site is identified in cases of occult breast cancer. Walter 
et al. reported the sensitivity of MRI and PET-CT as 89 and 63%, 
and the specificity as 74 and 91%, respectively for primary breast 
tumor [12]. 18F-FDG PET/CT can completely stage the disease 
which prognosticates the outcome and may identify other possible 
sites of primary tumors. In the above case with isolated right axillary 
lymph node metastasis 18F-FDG PET/CT contributed significantly 
in early detection of occult primary in the right breast and it had 
an important impact on patient management.
Figure 1A–C. Maximum intensity projection images of 18F-FDG PET 
(A) and axial sections of fused PET/CT and CT images (B and C) 
did not show any abnormal radiotracer uptake suggestive of primary 
malignancy or metastases
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Figure 2A–E. Maximum intensity projection images of 18F-FDG PET 
(A) shows abnormal increased FDG uptake in right breast (arrow) and 
right axillary region (bold arrow). Axial sections of fused FDG PET/CT 
and CT images (B and C) show a small subcentimeter soft tissue 
nodular lesion in upper outer quadrant of right breast with increased 
FDG uptake (arrow) suggestive of primary malignant disease and 
figures (D and E) show subcentimeter right subpectoral lymph node 
with increased FDG uptake suggestive of locoregional metastasis
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Figure 3A, B. Hematoxylin and eosin stained sections from the tumor 
showing nests and tubules of malignant ductal epithelial cells (100 ×) (A). 
Tumor cells show moderate nuclear pleomorphism (200 ×) consistent 
with infiltrating ductal carcinoma (B)
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